Growth hormone & belly fat
Tesamorelin
The one studied for visceral fat
Format
Add a refill for your pen
Tesamorelin 20 mg · +AED 765 each
Quantity — buy more, save more
Other quantity
Any mix counts: items from other products add up too.
Frequently paired with
Tap Add — each one counts toward your bundle saving.
Ipamorelin 10 mg
AED 730
Add another item from the catalogue
Pens are added as the reusable pen; change the format on the product page if you prefer.
A stabilised growth-hormone releasing analogue built to resist enzymatic breakdown, so the signal lasts longer. Best known in the literature for visceral-fat research.
Research use only. Supplied for laboratory and analytical research. Not a medicine or supplement, and not for human or animal use. We don't give dosing or clinical advice. Read the terms
- Presentation
- Lyophilised powder, reconstituted — 3 mL pen
Manufactured under controlled research-grade conditions. For documentation or questions about this compound, contact us on WhatsApp.
Published research
- Human trial
In a randomised, placebo-controlled trial in 412 adults with HIV and abdominal fat accumulation, tesamorelin reduced visceral fat by about 15% and improved triglycerides and cholesterol ratios.
Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007. PMID 18057338
- Human trial
In a randomized placebo-controlled trial of 404 people with HIV and excess abdominal fat, daily tesamorelin reduced visceral fat over 6 months, by about 18% at 12 months in those who continued; the reduction was lost after switching to placebo.
Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes. 2010. PMID 20101189
- Human trial
A pooled analysis of two phase 3 trials in 806 people with HIV and excess abdominal fat found that tesamorelin reduced visceral fat versus placebo at 26 weeks, without significant change in abdominal subcutaneous fat.
Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology and Metabolism. 2010. PMID 20554713
- Human trial
In a randomised, placebo-controlled trial in adults with HIV and abdominal fat accumulation, tesamorelin reduced visceral fat and modestly reduced liver fat over six months.
Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014. PMID 25038357
Short summaries of published studies, with links to the original papers. Results in animals or cells may not apply to people. This is not medical advice and not a guide to use.
All research on Tesamorelin